Third-generation EGFR inhibitors, represented by Osimertinib, have saved the lives of countless cancer patients and have been approved by major regulatory agencies for the treatment of EGFR T790M-positive cancer [20], However, Osimertinib resistance is surfacing as treatment is rolled out. Here, EGFR is linked to cancer.